Neurology research

Stroke: Women remain underrepresented in clinical trials

A new study shows that women are underrepresented in stroke clinical trials relative to the number who have strokes in the general population.

Photo
Illustration of a hemorrhagic stroke

Image source: Shutterstock/Artemida-psy

The research is published in Neurology, the medical journal of the American Academy of Neurology. “Making sure there are enough women in clinical studies to accurately reflect the proportion of women who have strokes may have implications for future treatment recommendations for women affected by this serious condition,” said study author Cheryl Carcel, MD, of The George Institute for Global Health in Sydney, Australia. “When one sex is underrepresented in clinical trials, it limits the way you can apply the results to the general public and can possibly limit access to new therapies.” 

The study looked at 281 stroke trials with at least 100 participants conducted between 1990 and 2020. The total number of participants was 588,887, of whom 37.4 % were women. The average prevalence of stroke in women across the countries included was 48%. Results were calculated in participation-to-prevalence ratio, a relative measure that weights the percentage of women in a trial compared to their proportion in the total population with that disease. It’s a simple way to tell if a research project has recruited enough women to be able to make accurate conclusions about the findings. A ratio of one means the percentage of women in the study is the same as the percentage of women with the disease in the general population. An acceptable range for an ideal ratio of female participation is between 0.8 and 1.2.

We will only achieve more equitable representation of women in clinical trials when researchers look at the barriers that are keeping women from enrolling in studies and actively recruit more women

Cheryl Carcel

Researchers found that overall, women were represented at a lower proportion relative to their prevalence in the underlying population, with a ratio of 0.84, and this did not change over time. They found the greatest differences in trials of intracerebral hemorrhage, with a ratio of 0.73; trials in which the average participant was below 70 years of age, with a ratio of 0.81; non-acute interventions, with a ratio of 0.80; and rehabilitation trials, with a ratio 0.77. “Our findings have implications for how women with stroke may be treated in the future, as women typically have worse functional outcomes after stroke and require more supportive care,” Carcel said. “We will only achieve more equitable representation of women in clinical trials when researchers look at the barriers that are keeping women from enrolling in studies and actively recruit more women. People who fund the research also need to demand more reliable, sex-balanced evidence.” A limitation of the study is that it included only studies registered on a U.S. government website and may not have captured all stroke trials. 


Source: American Academy of Neurology

14.10.2021

Read all latest stories

Related articles

Photo

Antisense therapy update

Huntington's disease: setback for study of promising agent

Roche announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen (previously IONIS-HTTRx and RG6042) in manifest Huntington’s disease (HD). The decision was…

Photo

More attempts, worse outcomes

Removing blood clots after stroke: Why the first try counts

After a stroke, doctors can try to remove clots in blood vessels to keep blood flowing freely to the brain. But even though most of these procedures are successful, less than half of people have a…

Photo

Rehabilitation

Hope for patients in vegetative and minimally conscious states

Non-invasive brain stimulation is to be trialed for the first time alongside advanced brain imaging techniques in patients who are minimally conscious or in a vegetative state. The study builds on…

Related products

Canon - HIT Automation Platform

Artificial Intelligence

Canon - HIT Automation Platform

Canon Medical Systems Europe B.V.
mediaire – mdbrain

Artificial Intelligence

mediaire – mdbrain

mediaire GmbH
Subscribe to Newsletter